Financial News
Merck says experimental RSV treatment protected infants in trial, paving way for potential approval
October 17, 2024 at 18:00 PM EDT
Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
